Hormone health (testosterone and menopause)
Menopause and perimenopause specialty launched in October 2025 under the Hers brand. Low-testosterone care was also launched in 2025.
What it is
Prescription treatment plans for low testosterone in men and for menopause and perimenopause in women. Care is directed by a licensed provider who adjusts the plan over time. Menopause options named by the company include estradiol and progesterone in pill, patch or cream form.↗ source
Why it matters to the stock. Hormone health extends the subscription model into longer-term treatment, which the company says can deepen customer relationships. Its revenue contribution is not broken out.
News
No stories tagged to this project yet.